CellAssist Provids Imaging, Analytics, and Documentation for Reproducible Cell Culture: Thrive Biosciences Launches

October 9, 2020

CellAssist which enables cell culture researchers to image, analyze, and document all cells, plates, reagents, and workflow details in a centralized database has been launched. The news was announced today. The CellAssist was developed by Thrive Bioscience, an innovator in cell culture systems, in collaboration with several highly-regarded academic institutions.

The CellAssist raises the bar for adherent cell culture by imaging and analyzing all the cells in a plate, not just cells chosen during typical manual inspection. Minutes after inserting a standard multi-well plate, the CellAssist captures, analyzes and displays hundreds of high-resolution images of cells at multiple magnifications, using phase contrast or bright-field. The visualization and analysis software allow researchers to comprehensively review images and metrics of the entire history of a project from one’s office or laboratory.

“The CellAssist solves cell culture problems widely experienced by researchers and laboratory managers, including inconsistent and partial imaging of plates of cells, a lack of objective metrics, and incomplete documentation,” said Thomas Forest Farb-Horch, Thrive Bioscience CEO and Co-Founder. “The CellAssist enables reproducible cell culture by capturing comparable images over time with barcoding and time-stamped documentation.”

“In cell biology, many of the important questions are raised after experiments are completed,” explained Steven Sheridan, Ph.D., Director, Platform for Cellular Modeling of Neuropsychiatric Disease, Center for Genomic Medicine, Massachusetts General Hospital. “With the CellAssist, we capture images and data, systematically and without the limitations that would later restrict our inquiries and insights. The database of images with related documentation becomes a valuable asset that helps us understand, analyze, and archive cellular metrics, unlike what we have previously achieved.”

Thrive Biosciences notes the CellAssist is available for shipment internationally.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”